Nanotechnologies:  Advances and Perspectives

 

 

 

 

International Nanobiological Testbed

 

The INT - International Nanobiological Testbed is a Company organized under the British laws, and its registered office is in London, UK. It was founded on 10th December, 1997, as a result of a scientific effort started in 1987 with the earlier formulation of Molecular Nanotechnology aims and scope by a small group of scientists from the UK, USA, Russia and Italy, who began at that time to investigate the field of molecular mesoscopic physics with particular application to miniaturization for space missions, to life sciences and to new views concerning computing science.

After some years of pioneering research and debates in congresses organized mainly in USA, when from such efforts two new branches were beginning to emerge and a remarkable number of scientists throughout the world were becoming interested in them, i.e. Nanotechnology and Nanobiology, the idea matured in our earlier group of scientists of founding a company devoted to the transformation of leading-edge theoretical nanoscale concepts into practical technologies, by working at the boundary between what had already been proved theoretically and what should have to be proved to definitely make it into a material, a device or a system featuring nanoscale structurally accuracy, and into a process to make them, or into nanoscale control capabilities of biological structures and processes. Accordingly, our R&D core competencies are concerned with both the theoretical and the practical sides of nanoscale sciences, and in the main of Nanobiology, because the ultimate goal we are pursuing is an understanding of life on the mesoscopic level, the development of practical nanobiotechnologies and of the capability of working at the subcellular structure level through nanomechanical devices, and the attainment of Molecular Manufacturing, i.e. the ability to build micro- and macroscopic objects with molecular-level accuracy as a bottom-up technology, both through the so-called “wet Molecular Nanotechnology”, relying on biomacromolecules and on supramolecular structures, and “dry Molecular Nanotechnology”, relying on artificial nanomechanical machines.

Our vision and mission statement contemplates R&D concerning both projects designed in-house and projects suggested by our customers. Cooperation with academies and the furthering of industrial-academic interaction is our constant effort. We can also consider cooperation with universities for introducing courses in nanosciences and nanotechnologies at proper levels in the faculties of science and engineering. In addition to the finding of suitable investments and the setting forth of joint ventures on an international scale, it is also our business to give advice on intellectual property rights concerning Nanotech findings, and to stimulate the optimal exploitation of intellectual property rights in such emerging branches. Indeed, anyone of such findings is likely to be of the essence for further developments and so to be a controlling factor in further industrial and market enterprises. Biomedicine, biotechnologies, micromechanics and microengineering can largely benefit from the nanoscale approach.

The exploration of the technical and cost-effective possible patterns from microsystems to nanotechnology and for nano-to-micro integration technologies, as well as the study of

biomimetic technologies for the aerospace industry and of present biomedical technologies that would take advantage from introduction of nanoscience principles are our major interests at present. We work out our projects at present through the R&D Department, the Patent Origination and Management Department, and the Financial and Commercial Department.

The Company has been asked to develop some projects concerning nanoscale and nano-to-micro integration systems - the technical proposals and the business plans as relative - by a number of academies and industrial companies in the UK. With the increase in the advances in nanoscience and nanotechnologies and the corresponding increase of investments in such fields for a variety of applications, the INT - International Nanobiological Testbed Ltd. Board of Directors and its Chairman are now planning to expand their activities in the USA. The international scope and intentions of the Company is expressed in the name of the Company itself.

Present Director of the R&D Department is Dr. Salvatore Santoli;

More details: http://www.nanobiology.com       e-mail: intitsnt@uni.net